AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00180297 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endotak Reliance G
Description: Reliance G is a defibrillation lead to be placed in the right ventricle.
Study NCT00180297 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endotak Reliance G
Description: Reliance G is a defibrillation lead to be placed in the right ventricle.
Study NCT05385445 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Audit and Feedback
Description: The investigators conducted a clustered randomized trial of primary care providers in Manitoba, Canada participating in the Manitoba Primary Care Research Network (MaPCReN) to assess the impact of Audit \& Feedback interventions to change prescribing and laboratory ordering.
Study NCT02153112 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GI.1/GII.4 (50/50)
Description: Norovirus GI.1/GII.4 (50 μg/50 μg) bivalent VLP vaccine combined with 500 μg aluminum hydroxide for IM injection
Study NCT02153112 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GI.1/GII.4 (50/150)
Description: Norovirus GI.1/GII.4 (50 μg/150 μg) bivalent VLP vaccine combined with 500 μg aluminum hydroxide for IM injection
Study NCT02153112 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo saline solution
Study NCT01721642 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Apica Cardiovascular ASC Access, Stability and Closure Device
Description: Access, stabilisation and closure of trans-apical approach for TAVI
Study NCT01643811 — intervention group
Intervention type: PROCEDURE
Intervention: gastrectomy
Description: subtotal gastrectomy with gastroduodenostomy or loop gastrojejunostomy or Roux Y gastrojejunostomy total gastrectomy with Roux Y esophagojejunostomy
Study NCT01643811 — intervention group
Intervention type: PROCEDURE
Intervention: Endoscopic submucosal dissection
Description: endoscopic submucosal dissection
Study NCT00309842 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: All patients will receive G-CSF 5 mcg/kg/day intravenously(IV) (dose rounded to vial size) based on the actual body weight IV beginning on day +1 after umbilical cord blood (UCB) infusion. G-CSF will be administered daily until the absolute neutrophil count (ANC) exceeds 2.5 x 10\^9/L for three consecutive days.
Study NCT01400243 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine
Description: Nicotine patch 7mg
Study NCT00309842 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Cyclophosphamide to be administered with high volume fluid flush and mesna (MT(S) 9006) at 10:00am, or per institutional routine, on days-7 and -6 after fludarabine. Cyclophosphamide 60mg/kg/day intravenous (IV) x 2 days, total dose 120 mg/kg (days -7 and -6) Dosing is calculated based on Actual BodyWeight (ABW) unless ABW > 30 kg above Ideal BodyWeight (IBW), in which case the dose should be computed using adjusted body weight.
Study NCT00309842 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine
Description: Patients will receive cyclosporine (CSA) therapy beginning on day -3 maintaining a level of > 200 ng/mL. For adults the initial dose will be 2.5 mg/kg intravenously (IV) over 2 hours every 12 hours. For children \< 40 kg the initial dose will be 2.5 mg/kg IV over 2 hours every 8 hours.
Study NCT00309842 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Description: Fludarabine 25 mg/m2/day intravenously (IV) x 3 days, total dose 75 mg/m2 (days -8 to -6);
Study NCT00309842 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil
Description: All patients will begin mycophenolate mofetil (MMF) on day -3. Patients ≥ 40 kilograms will receive MMF at the dose of 3 grams/day divided into 2 or 3 doses (every 12 or 8 hours).~Pediatric patient (\<40 kilograms) will receive MMF at the dose of 15 mg/kg three times a day.
Study NCT01400243 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Patch
Description: Placebo patch
Study NCT00309842 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: umbilical cord blood transplantation
Description: The product is infused via intravenous (IV) drip directly into the central line without a needle, pump or filter.
Study NCT00309842 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: total-body irradiation
Description: The recommended TBI is 165 cGy given twice daily for a total dose of 1320 cGy (days -4 to -1).
Study NCT00561080 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Zostavax
Study NCT03946904 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Er,Cr:YSGG Laser
Description: Patients with towo similar size lesions of either Class I or class v cavities selected as subjects. in the same appointment, both cavities are prepared by the Er'Cr:YSGG. one lesion was prepared with high power laser setting first to ablate the enamel, dentin, and caries. the other lesion was prepared with low power setting to start and is aimed at applying low level laser therapy (LLLT) first before using high power.
Study NCT04460547 — intervention group
Intervention type: DRUG
Intervention: Convalescent Plasma Transfusion
Description: Convalescent Plasma Transfusion to COVID-19 infected patients.
Study NCT04460547 — intervention group
Intervention type: DRUG
Intervention: Hydroxychloroquine
Description: Hydroxychloroquine administration to COVID-19 infected patients.
Study NCT04460547 — intervention group
Intervention type: DRUG
Intervention: DAS181
Description: DAS181 administration to COVID-19 infected patients.
Study NCT04460547 — intervention group
Intervention type: DRUG
Intervention: Ivermectin
Description: Ivermectin administration to COVID-19 infected patients.
Study NCT04460547 — intervention group
Intervention type: DRUG
Intervention: Interferon Beta-1A
Description: Interferon Beta-1A administration to COVID-19 infected patients.
Study NCT01736150 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: * Starting dose of 1 tablet (800mg), three times per day (2.4g/day)with meals.~* If serum phosphorus is higher than 5.5 mg/dL on Visit 3, 4, or 5, then dose increased by one additional tablet (800 mg). Three times daily with meals.
Study NCT01736150 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevelamer carbonate
Description: * Starting dose 1 tablet (800 mg), three times per day (2.4 g/day) with meals.~* If serum phosphorus is higher than 5.5 mg/dL on Visit 3, 4, or 5, then dose increased by one additional tablet(800mg).Three times daily with meals.
Study NCT03330522 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Love, Sex, & Choices video series
Description: Love, Sex, and Choices was written and scripted by the study team and underwent pilot testing in the target population. The series was divided into 15-to-20 minute episodes that were streamed weekly. The principles of reducing HIV risk were communicated through the characters and high risk situations. The lead characters model how women become more powerful, meaning more aware of themselves as worthy of respect, making choices intentionally, feeling free to pursue their intentions, and involving themselves in creating change. This process leads to higher power sex scripts in the characters, meaning pursuing intentional choices and health promoting behaviors. The lead characters model open communication about HIV testing with a resistant partner, and initiating condom use.
Study NCT03330522 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Messages in text
Description: The comparison group received 12 weekly HIV health promotion written messages over the smartphone. The messages were based on prevailing CDC recommendations and the theoretical framework. An example is: Sexual health means respecting your own rights and feelings. Feeling pressured to have sex means limiting your choices and your freedom to love safely. .... If he doesn't like you being you, it may be time to walk. Other messages provided instructions on the correct condom use and the importance of HIV testing. The 12 messages were reviewed by ten African American and Latina undergraduate nursing students for ease of comprehension.
Study NCT03204305 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 11C-OMAR
Description: 11C-OMAR is a PET radiotracer that binds to cannabinoid type 1 receptors (CB1R). It is an analog of the CB1R antagonist/inverse agonist rimonabant. 11C-OMAR was developed, synthesized and validated for inhuman use at the Johns Hopkins University PET center.
Study NCT03204305 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cannabis
Description: Cannabis will be administered to cannabis users. Doses include 0 and 25 mg THC.
Study NCT00954902 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High Antioxidant Spice Blend
Description: 14.5 g spice blend incorporated into a delivery meal including: cloves, cinnamon, oregano, rosemary, ginger, black pepper, paprika, garlic powder, and turmeric.
Study NCT00954902 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Trier Psychological Stressor
Description: This is a psychological stressor that is used to invoked stress responses in human subjects. Subjects are told they are taped and evaluated and deliver the speech in front of a trained panel of judges.
Study NCT00954902 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trier Psychological Stressor
Description: This is a psychological stressor that is used to invoked stress responses in human subjects. Subjects are told they are taped and evaluated and deliver the speech in front of a trained panel of judges.
Study NCT00954902 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Placebo antioxidant concentrate
Description: Placebo capsules
Study NCT00455429 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo capsules to JNJ-26113100 (50 milligram \[mg\]) orally once daily or 100 mg orally once daily or 100 mg orally twice daily or 250 mg orally twice daily for 6 weeks.
Study NCT00455429 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-26113100 (50 mg) once daily
Description: JNJ-26113100 (50 mg) capsules orally once daily for 6 weeks.
Study NCT00455429 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-26113100 (100 mg) once daily
Description: JNJ-26113100 (100 mg) capsules orally once daily for 6 weeks.
Study NCT00455429 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-26113100 (100 mg) twice daily
Description: JNJ-26113100 (100 mg) capsules orally twice daily for 6 weeks.
Study NCT00455429 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-26113100 (250 mg) twice daily
Description: JNJ-26113100 (250 mg) capsules orally twice daily for 6 weeks.
Study NCT04183920 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cranberry juice
Description: cranberry juice cocktail provided by Ocean Spray Cranberries, Inc.
Study NCT04183920 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo juice
Description: apple juice added with flavor and colorants provided by Ocean Spray Cranberries, Inc.
Study NCT03388294 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parents and Infants Engaged
Description: A novel in-home parent coaching intervention addressing transactions between pre-linguistic communication and sensory reactivity in infants at-risk for autism and other NDs on the one hand, and parent responses to infant cues on the other hand, using live coaching and video feedback methods.
Study NCT03434847 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Education
Description: Participants who receive perioperative educational to address their expectation about their postoperative pain will have improved pain-related postoperative outcomes.
Study NCT01764009 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: naked DNA coding for protein AMEP
Description: injections 28days interval of 3 increasing doses of plasmid with electrotransfer
Study NCT00827983 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone
Description: 25 mg, s.c., once à day
Study NCT00827983 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Progesterone
Description: 90 mg, vaginally, once à day
Study NCT01216943 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bimatoprost/brimonidine tartrate/timolol fixed combination ophthalmic solution
Description: One drop of Triple Combination Therapy (bimatoprost/brimonidine tartrate/timolol fixed combination ophthalmic solution) administered to each eye, twice daily for 12 weeks.
Study NCT02467920 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: glargine + exenatide
Description: glargine ( once-daily subcutaneous injection at bedtime) combination with exenatide (subcutaneous injection, twice-daily)
Study NCT02297269 — intervention group
Intervention type: DEVICE
Intervention: laparoscopic surgery
Description: the method of surgery is conducted by laparoscope with proper pressure of pneumoperitoneum instead of opening the abdomen.
Study NCT02297269 — intervention group
Intervention type: DEVICE
Intervention: open surgery
Description: the method of surgery is conducted by surgical instruments to open the abdomen.
Study NCT01002950 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACU-4429
Description: ACU-4429 tablets (2, 5, 7, or 10 mg) taken orally once daily for 90 days
Study NCT01002950 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo
Description: Matching placebo tablets taken orally once daily for 90 days
Study NCT03301038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin
Description: Rifampin 5 mg/kg (max 300 mg) daily for 8 weeks, followed by rifampin 10 mg/kg (max 600 mg) daily for 8 weeks.
Study NCT03925740 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MI Varnish
Description: Application of MI varnish material versus the standard 1.23% APF.
Study NCT03925740 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PreviDent Varnish
Description: Application of PreviDent Varnish material versus the standard 1.23% APF.
Study NCT03925740 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1.23% APF
Description: Standard 1.23% APF application
Study NCT04718142 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: vNEP
Description: Apply vNEP therapy to the anterior surface of the throat with a variable negative pressure ranging from -20 cmH2O up to -35 cmH2O and vNEP devices of varying shapes and sizes.
Study NCT02441608 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: KL029 Intimate Lubricant Gel
Description: All the volunteers will receive the application of four dressings (3 placebos and 1 containing the tested product). After a certain period of time, photoirritation and photosensitization will be measured through the evaluation of tested region.
Study NCT04830787 — intervention group
Intervention type: OTHER
Intervention: no intervention
Description: there is no intervention, we just chose patients diagnosed with hypertrophic cardiomyopathy and underwent CAG, and patients without hypertrophic cardiomyopathy as control ,the two groups are matched with age, gender and hypertension.
Study NCT01239706 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NTx 265
Description: 10,000IU of hCG, every other day for three doses followed by 4000IU once daily for three days of erythropoietin
Study NCT04251221 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Alcohol Challenge
Description: Subjects will drink an alcohol dose designed to achieve a BAL of 0.08
Study NCT00762242 — intervention group
Intervention type: PROCEDURE
Intervention: blood sampling and brachial artery ultrasound
Description: Intravenous blood sampling will be performed before and 15 seconds, 30 seconds, 1,2,5,10,and 30 minutes following an ischemic stimulus (inflation of a blood pressure cuff to suprasystolic pressure for 5 minutes)~Brachial artery ultrasound imaging will be performed before and 1 minute after a 5 minute ischemic stimulus, to assess endothelium-dependent vasodilation of the brachial artery.~Following completion of blood sampling, an additional resting image of the brachial artery will be obtained. Sub-lingual nitroglycerin will be administered, and the artery will be imaged again after 3 minutes, to assess endothelium-independent vasodilation.
Study NCT01685996 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zonisamide
Description: In addition to zonisamide vs placebo treatment, varenicline tablets will be dispensed with specific instructions to take at the recommended doses for smoking cessation Participants will receive brief smoking cessation counseling and referral to a quitline
Study NCT01685996 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT03332576 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DPX-Survivac
Description: SubQ injection
Study NCT03332576 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DPX-Survivac(Aqueous)
Description: SubQ injection
Study NCT03332576 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: PO BID
Study NCT02467920 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aspart 30
Description: aspart 30 ( subcutaneous injection, twice daily)
Study NCT01565941 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: IV insulin titration to target a blood glucose of 80-110 mg/dL
Study NCT01565941 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: IV insulin titration to target a blood glucose of 150-180 mg/dL
Study NCT02541136 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise
Description: Each exercise class consisted of a warm-up, an aerobic and a cool-down phase, supervised by a physiotherapist. The warm up and cool down phases consisted of 5-7 minutes of low intensity aerobic exercise, \< 40% Heart Rate Reserve (HHR), to allow the cardiopulmonary and musculoskeletal systems to adapt and recover, respectively.~The aerobic component initially consisted of 21 minutes at an intensity of 40-59% HRR and was progressed to 42 minutes at 55-75% HRR by week 8 until programme completion. All participants worked at the same intensity and duration at the various time points throughout the study. Continuous, rhythmic exercise using large muscle groups was prescribed using treadmills, cycle ergometers and other aerobic exercise that increased heart rate to its prescribed level.
Study NCT03797092 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Allogeneic adipose-derived stromal cells (CSCC_ASC)
Description: Active group
Study NCT03797092 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: No treatment
Study NCT03123614 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Loteprednol Etabonate 0.5% Oph Gel
Study NCT03123614 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone Acetate 1% Oph Susp
Study NCT04591743 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active TCS
Description: TCS active at 1 Hz on the right DLPFC for 6 weeks
Study NCT04591743 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo TCS
Description: Inactive TCS (placebo coil) at 1 Hz on right DLPFC for 6 weeks
Study NCT04591743 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nicotine treatment
Description: at least 21/14/7 mg/d + oral nicotine cp from 2 to 30 mg/d)
Study NCT04591743 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: nicotine treatment
Description: at least 21/14/7 mg/d + oral nicotine cp from 2 to 30 mg/d)
Study NCT04591743 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: EVA on craving, TCQ, QSU, BDI-II, CO tester, IGT, BART
Study NCT04591743 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Questionnaires
Description: EVA on craving, TCQ, QSU, BDI-II, CO tester, IGT, BART
Study NCT00973102 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Premarin IV
Description: One time dose of Premarin IV
Study NCT00973102 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One time dose of placebo.
Study NCT00376701 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avastin (Bevacizumab)
Description: Avastin 1.25 mg intravitreal
Study NCT00376701 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Intravitreal 1.25 mg
Study NCT00376701 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Intravitreal Avastin 1.25 mg and sham reduced fluence PDT
Study NCT03757130 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 598
Description: AMG 598 administered by subcutaneous injection
Study NCT02221284 — intervention group
Intervention type: DRUG
Intervention: Alogliptin
Description: Alogliptin tablets
Study NCT02450110 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spinal cord stimulation
Study NCT02725242 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol (160/4.5 μg/d)
Description: After the patients who have all criteria, they will be randomization to take Budesonide/formoterol (160/4.5 μg/d)
Study NCT03757130 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching to AMG 598 administered by subcutaneous injection